mice retained the wild-type Blm (Blm wt ) allele, indicating that the increased somatic LOH at Tsc1 was mediated by Blm haploinsufficiency. Renal lesions from a Blm-deficient background stained positively with anti-phospho-S6 ribosomal protein (Ser 240/244 ), suggesting that these lesions develop through the normal pathway of Tsc-associated tumorigenesis. This work shows the use of the Blm m3/m3 mice for inducing renal tumorigenesis, and the high levels (f87%) of LOH in the resultant tumors will help facilitate mapping of loci involved in tumor progression. (Cancer Res 2005; 65(22): 10179-82) 
Introduction
Bloom syndrome is a unique hereditary cancer predisposition disorder in which patients are predisposed to the development of many cancer types (1) . The Bloom syndrome gene, BLM, encodes an ATP-dependent, 3V to 5V helicase with homology to RecQ DNA helicase (2) . BLM resolves Holliday junctions, suppresses recombination in vitro, and is required for the fidelity of DNA doublestrand break repair (3) (4) (5) . Loss of BLM activity causes genomic instability characterized by an elevated frequency of the sister chromatid exchange (6) (7) (8) (9) . Recently, several investigators have exploited the high rate of mitotic recombination in Blm-deficient embryonic stem cells to allow powerful recessive genetic screens to be carried out in vitro (10, 11) . Furthermore, Luo et al. (12) have generated a mouse model of the human syndrome (Blm m3/m3 ) that is prone to a wide variety of cancers and can been used to induce colorectal tumorigenesis when crossed onto an Apc +/Min background. Here, we investigated whether Blm m3/m3 mice could induce tumorigenesis in extracolonic tissue by crossing with tuberous sclerosis 1-deficient (Tsc1 +/À ) mice that are predisposed to renal cystadenomas and carcinomas (13) . Renal tumors develop in Tsc1 +/À mice according to Knudson's ''two-hit'' hypothesis with somatic inactivation of the Tsc1 wt allele required for tumor development (13) . Normally, a diverse range of mechanisms (including nonsense, frameshift and deletion mutations, and epigenetic silencing) are implicated in the somatic inactivation of the wild-type allele of tumor suppressor genes, and this diversity of somatic alterations makes genetic mapping of loci involved in tumor progression problematic. We hypothesized that by crossing Tsc1 +/À mice onto a Blm-deficient background, we would increase the frequency of somatic loss of heterozygosity (LOH), thereby providing a convenient means of directly mapping genes involved in Tsc-associated tumorigenesis.
Materials and Methods
Animal care, genotyping, necropsy, and pathology. All procedures with animals were carried out in accordance with Home Office guidelines. Tsc1 +/À mice on a BALB/c background (backcross, N z 3; ref. 13) were crossed with Blm m3/m3 mice on a C57BL6 background (12) and Tsc1 +/À Blm +/m3 offspring were intercrossed to generate mice for subsequent analyses. DNA was extracted from mouse tail tips using the Qiagen (Chatsworth, CA) QIAamp DNA mini kits and genotyping was done as previously described (12, 13) . Necropsy analysis included macroscopic examination of the brain, heart, lungs, kidneys, liver, spleen, and uterus in 20 Tsc1 +/À Blm +/m3 and 20 Tsc1 +/À Blm m3/m3 mice at 3 to 6 and 9 to 12 months. Half of each organ was fixed and processed into paraffin wax, sectioned at 4 Am, and stained with H&E for microscopic inspection (tissues from 10 mice per genotype were analyzed microscopically at 3-6 and 9-12 months). Estimations of the average number of kidney lesions per mouse were determined as previously described (13) . The other half of the organs were snap-frozen in liquid nitrogen-cooled isopentane for laser capture microdissection (LCM).
Immunohistochemistry. Immunohistochemistry using anti-phospho-S6 ribosomal protein (Ser 240/244 ; Cell Signaling Technologies, Beverly, MA) was done as previously described (13) .
Somatic mutation analysis. Snap-frozen tissue was sectioned at 10 Am onto PEN (PALM) membrane covered slides and stained with toluidine blue. Tumor and normal tissue was microdissected (PALM LCM) and DNA extracted using the QIAamp DNA micro kits (Qiagen). LOH at the Tsc1 locus was assayed as previously described (13) , using wild type/mutant peak ratios of <0.67 or z1.3 as indicative of LOH (14) . To search for somatic intragenic Tsc1 mutations, the entire Tsc1 open reading frame (ORF) was amplified as 23 fragments (primer sequences are available upon request) and sequenced directly. LOH at the Blm locus was assayed by amplifying and directly sequencing the region encompassing the variant 4109-152 G>A, located in intron 18 of the Blm gene, 1 using the primers rs8248591/2F 5V -ACAGTTCTGAGAGGGGCTCA-3V and rs8248591/2R 5V -CCTAGCTTTCCA-CAGGCACT-3V . LOH of the Blm wt allele was determined by visual inspection of the 4109-152 G>A variant on the sequencing chromatograms by two independent investigators.
Simple sequence length polymorphism markers flanking Tsc1. Six highly polymorphic simple sequence length polymorphism (SSLP) markers flanking Tsc1 (D2Mit484, D2Mit451, D2Mit63, D2Mit37, D2Mit433, and D2Mit431) were analyzed in 18 and 14 tumors with LOH of the Tsc1 wt allele from Tsc1 +/À Blm m3/m3 and Tsc1 +/À Blm +/+ mice, respectively. Amplification of DNA from tumors was done as previously described (13), using a 25-cycle PCR reaction. Two microliters of PCR products were mixed with an ABI GS500 internal size standard and formamide loading buffer and run on an ABI3100 genetic analyzer. Results were analyzed using Genescan v.3.7 software, and LOH was determined as previously described (14) .
Statistical analysis. Comparisons of numbers of mice were done using the m 2 test. Lesion counts per mouse were compared using the MannWhitney confidence interval tests, and the frequency of LOH was compared using Fisher's exact test.
Results and Discussion
Blm deficiency has no effect on early Tsc1 +/À mortality. Tsc1 +/À Blm +/m3 mice were intercrossed. Genotyping showed that of the 360 offspring that survived until weaning, 204 were Tsc1 +/À and 134 were wild type (22 failed to be genotyped), indicating that all Tsc1 À/À and f24% of Tsc1 +/À mice died before weaning (P = 0.016). This finding was in agreement with our previous study (13) . Genotyping of the Blm allele in Tsc1 +/À animals showed no deviation from the expected 1:2:1 ratio (42 Blm +/+ , 90 Blm +/m3 , 52 Blm m3/m3 mice; 20 failed to be genotyped), indicating that there was no cumulative effect on early mortality for both Tsc1 and Blm deficiency.
Induction of renal tumors in Tsc1 +/À mice on a Blmdeficient background. We examined the kidneys of mice at 3 to 6 months by macroscopic inspection and microscopic analysis of five sections f200 Am apart. We observed a significant increase in renal tumors in Tsc1 +/À mice on a Blm-deficient background; 70% Fig. 1 ), indicating that these lesions develop through the normal pathway of Tscassociated tumorigenesis (13) .
Somatic mutation analysis of Tsc1 and mechanism of loss of heterozygosity. DNA was extracted from LCM kidney cystadenomas and carcinomas and analyzed for LOH at the Tsc1 locus using an IRES (mutant specific) and exon 8 (wild type specific) quantitative PCR assay, as previously described (13) . We observed significantly increased levels of somatic LOH of the Tsc1 wt allele in renal lesions from Tsc1 +/À Blm m3/m3 mice (53 of 61, 87%) compared with renal lesions from Tsc1 +/À Blm +/+ mice (61 of 118, 52%; P < 0.0001; Fig. 2 ). To determine the mechanism of increased somatic LOH in these lesions, we analyzed the extent of the LOH events using six SSLP markers on mouse chromosome 2, on which Tsc1 resides. Two of 18 tumors showing loss of the Tsc1 wt allele from Tsc1 +/À Blm m3/m3 mice remained heterozygous at the marker D2Mit431 located f5 cM upstream of Tsc1, whereas no tumors with loss of the Tsc1 wt allele from Tsc1 +/À Blm +/+ mice retained heterozygosity at any of the markers tested. This suggested that the LOH on a Blm-deficient background was mediated by mitotic recombination in agreement with Luo et al. (12) . We sought intragenic somatic Tsc1 mutations in DNA from the eight tumors from Tsc1 +/À Blm m3/m3 mice that retained the Tsc1 wt allele, by direct sequence analysis of the entire Tsc1 ORF. We generated highquality sequencing for z91% of the Tsc1 ORF for each tumor and identified a single intragenic somatic mutation, characterized as a 2-bp deletion in exon 22 (Tsc1 c.2872_2873 delTC). Therefore, in total, we identified f89% (54 of 61) of second-hit mutations in Tsc1 +/À Blm m3/m3 mice and clearly show that LOH mediated by mitotic recombination is the major mechanism of somatic mutagenesis in these animals. Further studies are warranted to determine the nature of the somatic mutations in the 11% of tumors from Tsc1 +/À Blm m3/m3 mice without LOH or coding region variations.
Do Tsc1 +/À Blm +/m3 mice show increased tumor burden? Goss et al. (15) showed that mice heterozygous for a targeted null mutation of Blm developed lymphoma earlier than wild-type littermates when challenged with murine leukemia virus and developed twice the number of intestinal tumors when crossed with Apc +/Min mice. Furthermore, Gruber et al. (16) showed that human carriers of a BLM mutation have an increased risk for colorectal cancer. In contrast, we did not observe significantly more renal lesions in Tsc1 +/À Blm +/m3 mice at 3 to 6 months when compared with Tsc1 +/À Blm +/+ mice that had previously been backcrossed (N > 3) onto two different backgrounds (BALB/c and C57BL6; ref. 13 ). However, we did observe significantly increased levels of somatic LOH of the Tsc1 wt allele in renal lesions from Tsc1 +/À Blm +/m3 mice (23 of 32, 71%; P = 0.03). To determine whether tumors from Tsc1 +/À Blm +/m3 mice had lost the Blm wt allele, we analyzed the polymorphism 4109-152 G>A, which lies within intron 18 of the Blm gene. Nineteen of 20 (95%) renal lesions from Tsc1 +/À Blm +/m3 mice that had lost the Tsc1 wt allele and were informative for this marker retained the Blm wt allele, indicating that the increased somatic LOH at the Tsc1 locus in these mice was mediated by Blm haploinsufficiency. 1 Our unpublished data. mouse, and no other lesions were seen after macroscopic and microscopic examination of the brain, heart, lungs, spleen, and uterus. Renal lesions have also been induced in other Tsc1 +/À mice (18) by using chemical mutagens, which cause a high frequency of somatic point mutations on the wild-type allele, and consistent with our observations, these animals do not seem to develop any unusual extrarenal tumors. These data indicate that the nature of the second hit does not affect the spectrum and distribution of extrarenal lesions in Tsc1 +/À mice. In conclusion, our study confirms the use of the Blm m3/m3 mouse for inducing tumorigenesis in cancer-prone mouse models. The high levels of LOH in the resultant tumors (and consequently low level of intragenic mutations) will help facilitate the mapping of loci that may play a role in tumor progression. 
